News Details

Contact

Rachel Darwin, Senior Manager, Public Relations

darwin@nccn.org, 267-622-6624

NCCN and AstraZeneca Seek Opportunities to Improve Outcomes in Advanced Ovarian Cancer

NCCN Oncology Research Program (ORP) issues request for proposals to improve quality of care for people with stage III, stage IV, and recurrent epithelial ovarian cancer. 

PLYMOUTH MEETING, PA [June 20, 2019] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) is collaborating with AstraZeneca, a global, science-led biopharmaceutical company, to further quality in cancer care for people with advanced ovarian cancer. This follows a recently announced and still active request for proposals, also in collaboration with AstraZeneca, on innovative approaches for improving care in unresectable stage III and IV non-small cell lung cancer. Letters of intent are due Monday, July 22, 2019, for this new opportunity, which is available to researchers at any of the 28 NCCN Member Institutions.

“Advanced and recurrent ovarian cancer remains a treatment challenge,” explained Wui-Jin Koh, MD, Chief Medical Officer, NCCN. “It’s currently the deadliest gynecologic cancer, and requires a coordinated, multi-disciplinary approach. With this project, we’re looking for research that focuses on how to optimize multiple facets of management effectiveness by harnessing innovative technologies or addressing knowledge gaps.”

Some areas of particular interest for proposals include:

  • Adhering to standard of care management
  • Delivering care through innovative methods (e.g. telemedicine and/or coordination of care between academic centers and community practices)
  • Improving adoption of appropriate genetic testing
  • Discovering new strategies for sharing and implementing novel findings expeditiously
  • Creating shared decision-making models
  • Improving the use of supportive services
  • Utilizing technology to enhance quality of life in patients

Proposals that are reproducible, scalable, rapidly implementable, and provide quantifiable outcome measures are preferred. NCCN ORP is also interested in discovering concepts to reduce financial toxicity, manage care across multiple facilities, increase clinical trial enrollment, and enhance shared decision-making and patient information.

The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer. Collaboration between NCCN Member Institutions is strongly encouraged in order to cultivate interactive sharing of knowledge and expertise, and to utilize the combined strengths of members. For more information and to read the entire Request for Proposals, visit NCCN.org/ORP.

# # #